<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cyclopentolate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00979</strong>&#160; (APRD00893)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00979/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00979/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00979.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00979.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00979.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00979.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00979.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00979">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#177;)-cyclopentolate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ciclopentolato</td><td>Spanish</td><td>INN</td></tr><tr><td>Cyclopentolatum</td><td>Latin</td><td>INN</td></tr><tr><td>&#945;-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>&#946;-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Cyclopentolate Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000476/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000476/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: RHKZVMUBMXGOLL-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 327.16012141</li>
              <li>Average Mass: 327.846</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000476">DBSALT000476</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>AK-PENTOLATE</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bell Pentolate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cyclogyl</td><td>Alcon</td></tr><tr><td>Cylate</td><td>Ocusoft</td></tr><tr><td>Mydrilate</td><td>Intrapharm</td></tr><tr><td>Ocu-Pentolate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pentolair</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Cyclomydril</td><td>Phenylephrine + Cyclopentolate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/muscarinic-antagonists">Muscarinic Antagonists</a></li>
<li><a href="/mesh/parasympatholytics">Parasympatholytics</a></li>
<li><a href="/mesh/mydriatics">Mydriatics</a></li></ul></td></tr><tr><th>CAS number</th><td>512-15-2</td></tr><tr><th>Weight</th><td>Average: 291.3853<br>Monoisotopic: 291.183443671</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>25</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>SKYSRIRYMSLOIN-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Tertiary Alcohols; Tertiary Amines; Cyclic Alcohols and Derivatives; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>tertiary alcohol; cyclic alcohol; carboxylic acid ester; tertiary amine; carboxylic acid derivative; ether; polyamine; enolate; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.</td></tr><tr><th>Pharmacodynamics</th><td>Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises.</td></tr><tr><th>Mechanism of action</th><td>By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia).</td></tr><tr><th>Absorption</th><td>Absorbed following ophthalmic administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9741</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8234</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6395</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7831</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6735</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9384</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5874</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7938</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7009</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6036</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9413</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9518</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8284
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8492
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.931
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4300 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9335
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.779
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Akorn inc</li>
<li>Alcon laboratories inc</li>
<li>Alcon universal ltd</li>
<li>Sola barnes hind</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>Pharmafair inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.alcon.com">Alcon Laboratories</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.eyecareandcure.com">Eye Care and Cure Corp.</a></li>
<li><a href="http://www.eyesupplyusa.com">Eye Supply Usa Inc.</a></li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.ocusoft.com">Ocusoft</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution / drops</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>